Fruhwald Friedrich M, Rehak Peter, Maier Robert, Watzinger Norbert, Wonisch Manfred, Klein Werner
Department of Internal Medicine, Division of Cardiology, University Hospital Graz, Auenbruggerplatz 15, A-8036 Graz, Austria.
Eur J Heart Fail. 2004 Dec;6(7):947-52. doi: 10.1016/j.ejheart.2004.02.004.
Treatment of chronic heart failure is based on the results of large clinical trials, which form the basis of treatment guidelines, such as those from the European Society of Cardiology (ESC). The aim of this study was to record treatment-modalities and the implementation of guidelines of chronic heart failure in clinical practice in Austria.
Overall 96 general physicians, specialists for internal medicine in private practice or in hospital outpatient departments participated in the survey. Physicians were asked to prospectively document 30 consecutive patients with chronic heart failure.
1880 patients were documented. The majority of patients were treated by general physicians (57%). Coronary artery disease was the most frequent aetiology for heart failure (47%). The most frequently used drugs were blockers of the renin-angiotensin-system (RAS-blocker including ACE-inhibitors and angiotensin-receptor-blockers, 78%), diuretics (76%) and beta-blockers (49%). Other drugs like digitalis and spironolactone were used infrequently. Average doses of ACE-inhibitors were approximately 90% of those recommended by the ESC, average doses of beta-blockers were approximately 50% of those recommended. Treatment among the three classes of physicians differed with respect to RAS-blockers and beta-blockers, which were used infrequently by general practitioners. Both groups of drugs were given more frequently to younger patients (<70 years) while digitalis was given more often to elderly patients.
Results from this survey suggest that Austrian physicians treating patients with heart failure use the appropriate drugs in dosages that are suggested by recently published guidelines (ACE-inhibitors and beta-blockers). However, dosages of spironolactone clearly differed from current recommendations.
慢性心力衰竭的治疗基于大型临床试验的结果,这些结果构成了治疗指南的基础,例如欧洲心脏病学会(ESC)发布的指南。本研究的目的是记录奥地利临床实践中慢性心力衰竭的治疗方式和指南的实施情况。
共有96名普通内科医生、私人执业或医院门诊部门的内科专家参与了此次调查。要求医生前瞻性记录30例连续的慢性心力衰竭患者。
共记录了1880例患者。大多数患者由普通内科医生治疗(57%)。冠状动脉疾病是心力衰竭最常见的病因(47%)。最常用的药物是肾素 - 血管紧张素系统阻滞剂(RAS阻滞剂,包括ACE抑制剂和血管紧张素受体阻滞剂,78%)、利尿剂(76%)和β受体阻滞剂(49%)。洋地黄和螺内酯等其他药物使用较少。ACE抑制剂的平均剂量约为ESC推荐剂量的90%,β受体阻滞剂的平均剂量约为推荐剂量的50%。三类医生在RAS阻滞剂和β受体阻滞剂的使用上存在差异,全科医生使用较少。这两类药物在年轻患者(<70岁)中使用更频繁,而洋地黄在老年患者中使用更频繁。
本次调查结果表明,奥地利治疗心力衰竭患者的医生按照最近发布的指南(ACE抑制剂和β受体阻滞剂)建议的剂量使用了适当的药物。然而,螺内酯的剂量明显不同于当前推荐剂量。